Abstract:Abstract Notch receptor-mediated signaling is essential for embryonic development and adult tissue homeostasis by regulating cell proliferation, differentiation and survival. Aberrant Notch signaling is linked to many epithelial cancers and hematological malignancies. For example, activated NOTCH1 mutations are detected in more than 50% of T cell acute lymphoblastic leukemia (T-ALL) patients. Since the constitutive activation of Notch signaling results in leukemic cell transformation and is required for the maintenance of the leukemic phenotype, the Notch pathway is a promising and highly specific molecular therapeutic target for T-ALL. We have previously identified the family of the MAML transcriptional co-activators as essential components of the core Notch transcription activation complex. The prototypic member MAML1 was found to be the major co-activator that regulates NOTCH1 oncogenic activities in leukemic cells. Hence, the modulation of MAML1 expression levels or functional activities is expected to affect Notch-induced leukemic initiation and progression. However, it remains unclear how MAML1 function is regulated. To gain insights into the molecular basis underlying MAML1 function, we undertook the task of identifying cellular factors that interact with MAML1 and characterizing their roles in regulating Notch signaling and Notch-mediated T cell leukemia. Through proteomic studies, we identified DDX5, an ATP-dependent DEAD-box RNA helicase, as a component in the MAML1 protein complex. Given the role of DDX5 as a transcriptional modulator, we reasoned that DDX5 might be a critical regulator of MAML1-mediated Notch target genes transcription. We showed that DDX5 interacts with MAML1 in vitro and in vivo, and is associated with the endogenous Notch1 transcription activation complex through interaction with MAML1. Lentiviral-mediated shRNA knockdown of DDX5 resulted in decreased expression of Notch target signature, along with reduced cell proliferation and survival in leukemic cells that carry activated NOTCH1 mutations. Our findings thus revealed an essential role of DDX5 in promoting efficient Notch-mediated transcription in leukemic cells where the Notch pathway is constitutively activated, suggesting that DDX5 might be critical for Notch-mediated T-ALL pathogenesis and could be a potential new target for modulating the Notch signaling in leukemia. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3388. doi:10.1158/1538-7445.AM2011-3388

Targeting DDX3X eliminates leukemia stem cells in chronic myeloid leukemia by blocking NT5DC2 mRNA translation

Targeting CaMKII-δ/DHCR24 Axis is a Novel Strategy Against Acute Myeloid Leukemia

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Chemoresistant Leukemia-Initiating Cell Expansion is Inhibited by Targeting Oncogenic Self-Renewal

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

RNA Helicase DHX15 Exemplifies a Unique Dependency in Acute Leukemia.

Super-enhancer Landscape Reveals Leukemia Stem Cell Reliance on X-box Binding Protein 1 As a Therapeutic Vulnerability.

The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia

Orphan Drug Development for Targeting Chronic Myeloid Leukemia Stem Cells

Ddx5 Modulates Notch Signaling Via Interaction With The Maml1 Co-Activator And Is Required To Optimal Notch Signaling In Leukemic Cells

A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells

DDX5 is a Positive Regulator of Oncogenic NOTCH1 Signaling in T Cell Acute Lymphoblastic Leukemia

Analysis of ceRNA networks and identification of potential drug targets for drug-resistant leukemia cell K562/ADR

Comparison of chronic myeloid leukemia stem cells and hematopoietic stem cells by global proteomic analysis

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

Eradication of Chronic Myelogenous Leukemia by Inactivation of the Polycomb Group Protein Ezh2

Declined Presentation Heterogeneous Nuclear Ribonucleoprotein D-like Promotes the Growth of Chronic Myeloid Leukemia Cells Via Pre-B-cell Leukemia Homeobox 1

Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6

Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia

Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia

Chronic Myelocytic Leukemia (CML) Patient-Derived Dendritic Cells Transfected with Autologous Total RNA Induces CML-Specific Cytotoxicity